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Mumps  vaccines  are  live  attenuated  viruses.  They  are  known  to  vary  in  effectiveness,  degree  of atten-
uation  and  adverse  event  proﬁle.  However,  the  underlying  reasons  are  poorly  understood.  We  studied
two  closely  related  mumps  vaccines  which  originate  from  the  same  attenuated  Jeryl  Lynn-5  strain  but
have  different  efﬁcacies.  Jeryl  Lynn-Canine  Kidney  (JL-CK),  produced  on  primary  canine  kidney  cells,  is
less  effective  than  RIT4385,  which  is  produced  on chicken  embryo  ﬁbroblasts.  JL-CK  and  RIT4385  could
be  distinguished  by a number  of in  vitro  and in  vivo  properties.  JL-CK  produced  heterogeneous,  gener-
ally  smaller  plaques  than  RIT4385,  but  gave  100-fold  higher  titres  when  grown  in cells and  showed  a
higher  degree  of  hydrocephalus  formation  in  neonatal  rat brains.  Sanger  sequencing  of JL-CK identiﬁed
14  regions  of heterogeneity  throughout  the  genome.  Plaque  puriﬁcation  of  JL-CK  demonstrated  the pres-
ence of ﬁve  different  Jeryl  Lynn-5  variants  encompassing  the  14 mutations.  One  JL-CK  mutation  was
associated  with  a small  plaque  phenotype,  the  effects  of the others  in  vitro  or in  vivo  were  less clear.  Only
4%  of  the  JL-CK  population  corresponded  to  the  parental  Jeryl  Lynn-5  strain.  Next  generation  sequencing
of  JL-CK  and  virus  before  and  after  growth  in  cell lines  or neonatal  rat brains  showed  that  propagation  in
vitro  or  in  vivo  altered  the  population  dramatically.  Our  ﬁndings  indicate  that  growth  of JL-CK in  primary
canine  kidney  cells  resulted  in  the  selection  of a mixture  of  mumps  virus  variants  that  have  different  bio-
logical  properties  compared  to the  parent  Jeryl  Lynn-5  virus.  We  also  report  three  previously  unknown
heterogenic  regions  within  the  N  gene  of  the  RIT4385  vaccine.
© 2015  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).. Introduction
Mumps  is caused by infection with a negative-strand RNA
aramyxovirus. Disease is characterised by pain and swelling of
he parotid gland(s) [1]. Mumps  is preventable by vaccination with
ive mumps  viruses (MuV) that have been attenuated by passage in
arious cell substrates [2–6]. MuV  vaccine strains vary in protec-
ive efﬁcacy, degree of attenuation [7] and adverse event proﬁles
8–11]. A correlate of protection in terms of neutralising antibody
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/).has not been established [12] and an animal model which mimics
human disease has yet to be identiﬁed [13–16].
The Jeryl Lynn vaccine strain is most widely used [1]. Attenuated
by serial passage in embryonated hens’ eggs and chicken embryo
culture [17], it has been shown to be a mixture of two  distinct but
related MuVs, JL-2 and JL-5 [18–20]. The Jeryl Lynn-5 (JL-5) compo-
nent was  passaged in chicken embryo ﬁbroblasts (CEFs) to produce
RIT4385 [21], which has the same efﬁcacy as the original Jeryl Lynn
vaccine [12] and a seroconversion rate of ∼94% [21].
The Jeryl Lynn-Canine Kidney (JL-CK) vaccine is also derived
from the Jeryl Lynn vaccine [22] but was passaged in primary canine
kidney cells [4,23], which is atypical for MuV  vaccine production.
Seroconversion after JL-CK vaccination was  only 75% 6–8 weeks
post-vaccination [22], increasing to 82% after 35 months [4]. JL-CK
has been associated with vaccine failure [24,25]. A large mumps
outbreak occurred in the Czech Republic between January 2005
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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nd June 2006 [26], despite high vaccination coverage with JL-CK,
uggesting the vaccine may  be over-attenuated [7].
MuV  adaptation to cell substrates is well known and we hypo-
hesised that propagation in primary canine kidney cells may  have
ltered the virus. We  compared the JL-CK and RIT4385 vaccine
iruses to identify differences. We  report genotypic and phenotypic
ariations between the two viruses, despite their shared origin.
e identiﬁed mutations and distinct virus subpopulations within
he JL-CK vaccine, which are likely a result of the virus’ passage in
rimary canine kidney cells. We  highlight that propagation of the
L-CK vaccine virus, both in vitro and in vivo, alters the composition
f the virus subpopulations, selecting certain MuV  subpopulations
ver others. We  also describe previously unknown mutations in the
IT4385 vaccine.
. Materials and methods
.1. Cell lines and viruses
African green monkey (Vero) and Madin Darby canine kidney
MDCK) cell lines were used as substrates for virus growth. JL-CK
accine was provided by the Ofﬁcial Medicines Control Laboratory-
rague, Czech Republic. Mu90, a clinical mumps  isolate passaged
our times on Vero cells, and RIT4385 were archived material held
t NIBSC. Infected cells were incubated at 35 ◦C, 5% CO2.
.2. In vitro growth kinetics
Vero cells were inoculated, incubated and viable cells measured
sing CellTiter 96® AQueous One Solution Cell Proliferation Assay
Promega). Vero or MDCK cells were inoculated in triplicate at a
ultiplicity of infection (MOI) of 0.0001, incubated and one plate
emoved daily for 7 days before clariﬁcation by centrifugation and
itration on Vero cells.
.3. Titration and plaque isolation of viruses
Viruses were titrated by plaque assay on Vero cells [27] with a 10
ay incubation period before ﬁxation/staining with methyl violet.
irus titres were calculated as plaque-forming-units (pfu) per ml.
laque sizes were compared using ImageJ software [28,29]. JL-CK
laques (n = 81) were picked to a conﬂuent monolayer of Vero cells
nd grown until cytopathic effect observed.
.4. RNA extraction, RT-PCR and Sanger sequencing
Viral RNA was extracted using Trizol® LS reagent (Life Tech-
ologies). RT-PCR assays were performed using QIAGEN® One-Step
T-PCR Master mix  (primers available upon request), amplicons
uriﬁed by QIAquick® Gel Extraction and sequenced (Euroﬁns
enomics, GmBH). Sequencing data was analysed using Lasergene
.0 – SeqMan (DNASTAR) and ClustalW (EMBL-EBI).
.5. Mass spectrometry (MS) and sequence analysis
JL-CK and RIT4385 were grown in Vero cells for 3 days,
ucrose gradient puriﬁed, subjected to SDS-PAGE before stain-
ng with Colloidal Blue (Life Technologies). Gel bands within
6–52 kDa (JL-CK, n = 2; RIT4385, n = 3) were excised, washed
nd trypsin-digested. Tryptic peptides were extracted and sub-
ected to online nano-LC/MS/MS analysis using a LTQ-Orbitrap
ass spectrometer (Thermo Scientiﬁc, UK) [30]. Mass spectra
ere processed and database searched using Proteome Dis-
overer v.1.2 (Thermo Scientiﬁc) and UniProt FASTA database.
 FASTA format of the JL-CK nucleoprotein with additionale 33 (2015) 4586–4593 4587
amino acids at the C-termini (HANTFPNNPNQNAQLQVGDWDEQIT-
DMIKP/KLTPIATIPGQSSHS) was created.
2.6. cDNA synthesis, PCR and deep sequencing
Random hexamer cDNA was  synthesised by Superscript III First
Strand cDNA Synthesis (Life Technologies). Fusion primers were
designed with universal tails (available upon request) to gener-
ate targeted amplicons using Phusion® High-Fidelity PCR Master
mix  (New England Biolabs). Amplicons were puriﬁed with Agen-
court AMPure XP Beads (Beckman-Coulter) and quantiﬁed using
Agilent High Sensitivity DNA assay. Puriﬁed amplicons were pooled
in equimolar concentration and libraries prepared by Nextera® XT
DNA Sample preparation Kit (Illumina), before analysis on an Illu-
mina MiSeq Sequencer.
2.7. Neurovirulence testing
Neonatal rat pups were inoculated intracerebrally [31] with
100 pfu either JL-CK, RIT4385, Mu90 or JL-CK variants. After 25
days, brains were removed and ﬁxed in 10% neutral-buffered for-
malin. Brains were processed and stained with haematoxylin/eosin
(Propath UK Limited) [29]. Hydrocephalus severity was calculated
as a percentage of the cross-sectional area of the ventricle from the
area of the whole brain using ImageJ [28]. All animal procedures
were performed in accordance with Institutional guidelines.
2.8. Statistical analyses
The in vitro growth data and in vivo neurovirulence data were
analysed using Student’s t test. The error bars represented the
standard error of the mean for each data point with a p value <0.05
considered signiﬁcant.
2.9. Accession numbers
The JL-CK variants have been designated GenBank® accession
numbers. JL-CK1, JQ946550; JL-CK2, JQ946551; JL-CK3, JQ946552;
JL-CK4, JQ946553 and JL-CK5, JQ946554.
3. Results
3.1. In vitro growth of JL-CK and RIT4385
Titration of MuV  is routinely performed on the interferon-
deﬁcient Vero cell line [27]. Plaques produced by JL-CK in Vero cells
were at least three times smaller than those formed by RIT4385
(Fig. 1A and B). JL-CK and RIT4385 growth and virus yield was mea-
sured in both simian (Vero) and canine kidney (MDCK) cells. Fig. 1C
demonstrates JL-CK and RIT4385 lysed Vero cells at similar rates,
with 50% lysis observed at 3.65 or 3.99 days, respectively. By day
7, JL-CK produced 100-fold more progeny virus in Vero (p < 0.0001)
and MDCK cells (p = 0.0365), Fig. 1D.
3.2. Isolation and sequence analysis of JL-CK virus variants
In order to identify genomic differences between the two
viruses, we  sequenced unpassaged JL-CK and aligned it against
the published sequence of RIT4385. Thirteen positions throughout
the JL-CK genome displayed polymorphic nucleotides, result-
ing in 10 predicted amino acid changes (nucleoprotein: E108D,
V529A, Ter550Q which extends the nucleoprotein by 21 amino
acids and incorporates L557P, phosphoprotein/V/I: N56T, matrix:
C244R, fusion: P93S and F295S based on two changes in adjacent
nucleotides, haemagglutinin-neuraminidase: E569K and large:
D311G), one silent mutation (L542L) and one mutation in the
4588 S.M. Connaughton et al. / Vaccine 33 (2015) 4586–4593
Fig. 1. (A) Plaque morphology after infection of Vero cells. Panel a represents JL-CK and Panel b represents RIT4385. JL-CK produced a mixture of small and large plaques
whereas RIT4385 formed a more homogeneous population of large plaques. (B) Measurement of plaque size of JL-CK and RIT4385 using ImageJ. The data shown is from JL-CK
plaques  (n = 25) and RIT4385 plaques (n = 33) (*p < 0.0001). (C) Growth kinetics of JL-CK and RIT4385 in Vero cells. JL-CK and RIT4385 were inoculated at MOI  0.0001 and lysed
Vero  cells at comparable rates. Viability of infected cells was expressed as the percentage of uninfected cells. Sigmoidal curves were ﬁtted to the data points to calculate 50%
cell  lysis using GraphPad Prism 5 software (3.65 days for JL-CK and 3.99 days for RIT4385). The 95% conﬁdence intervals overlapped (JL-CK, 3.89–4.42, RIT4385, 3.85–4.15
days).  (D) JL-CK and RIT4385 progeny virus titres in Vero and MDCK cells. Infections were performed in two independent experiments each in triplicate, cells were infected
at  MOI  0.0001 and progeny viruses were titred in Vero cells after 7 days. JL-CK produced more progeny viruses on both Vero and MDCK cells (*p < 0.0001, **p  = 0.0365),
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tompared with RIT4385 on the same cell line (unpaired, two-tailed t-test).
eader sequence (G/Ant92). We  found no polymorphisms in the gene
ncoding the small hydrophobic (SH) protein, which is highly vari-
ble between mumps  strains [32]. This indicated the presence of
ultiple JL-5 viruses, consistent with the mixed plaque morphol-
gy in Fig. 1A. We  conﬁrmed that the elongated nucleoprotein
ncorporating Ter550Q is expressed at the protein level. Using mass
pectrometry, we identiﬁed the C-terminus of the extended protein
LTPIATIPGQSSHS) in the JL-CK vaccine, but not in RIT4385, Table
1. The L557P mutation, which is located in the same peptide of
he elongated nucleoprotein of variant JL-CK5 (PTPIATIPGQSSHS),
as not detected due to the proline disrupting the trypsin digestion
otif.
Plaque puriﬁcation and sequencing the polymorphic regions in
1 plaques from JL-CK conﬁrmed the presence of the mutations
nd also identiﬁed an additional mutation leading to a change in
he nucleoprotein (K36R), Table S2. We  identiﬁed ﬁve virus vari-
nts (JL-CK1, JL-CK2, JL-CK3, JL-CK4 and JL-CK5) plus a parent-like
ariant, which was identical to the published sequence of RIT4385
nd found at only 4% frequency in the population. The predicted
mino acid changes, silent mutation and mutation in the non-
oding leader sequence in each variant, compared to the RIT4385
equence are depicted in Fig. 2.
The G/Ant92, C244R and E569K mutations are common to all
ariants. Each variant has in addition a variety of the other muta-
ions. The parent-like virus represents only 4% of the population(not shown). Some mutations are unique to one variant; K36R in JL-
CK1; N56T/P93S/D311G in JL-CK4 and V529A/L542L/L557P/F295S
in JL-CK5. The E108D mutation is found in variants JL-CK2-5 and
Ter550Q in variants JL-CK3-5 (Fig. 2).
3.3. Deep sequencing of JL-CK and RIT4385
To identify whether the plaque-puriﬁed virus populations are
represented at similar ratios in unpassaged JL-CK, we performed
amplicon-based deep sequencing of JL-CK and RIT4385 vaccines.
The frequency of each mutation determined by plaque puriﬁ-
cation (JL-CK) and deep sequencing of unpassaged virus (JL-CK
and RIT4385) is shown in Table 1. The mutations unique to
JL-CK5 (V529A, L542L, L557P, F295S) all reduced from 26% (unpas-
saged) to 4% in plaques. The K36R mutation, unique to JL-CK1,
increased from undetectable (Sanger) and 9.1% (deep sequencing)
in unpassaged virus to 46% in plaques. JL-CK4 represented 38%
of the plaques isolated and JL-CK4 mutations (N56T/P93S/D311G)
occurred at similar frequencies in the unpassaged virus (40.5,
45.3 and 43.4%, respectively). E108D, found in all variants other
than JL-CK1, was  identiﬁed at 51% in plaques but at 86.6% in
unpassaged virus. The G/Ant92/C244R/E569K mutations present
in all JL-CK variants occurred as frequently in the unpassaged
vaccine as in plaques, as did the N56T/P93S/D311G mutations
(JL-CK4).
S.M. Connaughton et al. / Vaccine 33 (2015) 4586–4593 4589
Fig. 2. Schematic representation of the JL-CK virus variants plaque-puriﬁed from the JL-CK vaccine. The variants are numbered JL-CK1-5 in order of increasing number of
mutations. Locations where the sequence differs from the published RIT4385 genome are indicated. Those positions on the genome which are linked are marked *(G/Ant92,
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f244R  and E569K), #(N56T, P93S, D311G) and +(V529A, L542L, L557P, F295S). The
he  unpassaged JL-CK vaccine. The Ter550Q mutation results in an extended nucleo
ubpopulations is expressed as a percentage of the 81 plaques isolated from Vero c
We  also found three of the mutations in the RIT4385 vaccine
V529A, L542L and L557P at 6.2%, 16.6% or 21.3% respectively),
able 1. We  did not detect Ter550Q in RIT4385.
.4. Variant population dynamics after in vitro passage
We  investigated changes to the virus subpopulations after pas-
age in Vero and MDCK cells. Deep sequencing was  performed on
ell lysates 3 days post-infection (d.p.i.) with JL-CK or RIT4385,
he point at which cytopathic effect was evident, which con-
rmed the Sanger sequencing plaque data (10 d.p.i.), Table 1.
36R increased from 9.1% in unpassaged virus to 27% in Vero
nd 18.8% in MDCK cells. The JL-CK4 variant appeared consistent,
able 1
utation frequencies identiﬁed by deep sequencing of JL-CK and RIT4385 compared to S
laques,  10 days post-infection (d.p.i.) are shown in the top section. Virus in Vero and M
dentiﬁed by deep sequencing of neonatal rat brains 4 d.p.i. with JL-CK virus, are shown in
Substrate Virus Mutation frequency (%)
Leader K36R E108D V529A L542L Ter
Unpassaged JL-CK 96.7 9.1 86.6 27 26.2 74.
RIT4385 n.d. n.d. n.d. 6.2 16.6 n.d
Vero
Plaques#
JL-CK 98a 46b 51 4 4 44 
Vero*
3 d.p.i.
JL-CK 94.5 27.0 70.5 10.4 9.5 48.
RIT4385 n.d. n.d. n.d. 11.6 21.5 n.d
MDCK*
3 d.p.i.
JL-CK 84.1 18.8 68.3 23.3 23.0 53.
RIT4385 n.d. n.d. n.d. 2.9 31.6 n.d
RNV1  JL-CK 100 69.6 33.4 1.3 1.3 26.
RNV2  100 93.9 5.4 n.d. n.d. 18.
RNV3  100 94.3 6.6 n.d. n.d. 3.1
# 81 plaques were sequenced except a 49 plaques and b 79 plaques due to lack of mater
requencies detected in 2 independent deep sequencing assays, n.d. not detected, d.p.i da mutation was identiﬁed in plaques, it was  not identiﬁed by Sanger sequencing of
in open reading frame, incorporating the L557P mutation. The ratio of the different
d Sanger sequenced.
with N56T/P93S/D311G occurring at 42.2%, 39.9% and 35%, in Vero
lysates and 31.7%, 31%, and 29.5% in MDCK lysates, although direct
linkage cannot be conﬁrmed, it suggests selection of JL-CK1 and JL-
CK4 in Vero cells. All other mutations reduced in frequency from
unpassaged virus and were in line with the plaque frequencies
shown in the top section of Table 1.
The frequencies of mutations observed in MDCK cell lysates
were more in line with unpassaged JL-CK virus, suggesting the
canine cell line supports growth of all variants. The mutations
identiﬁed in unpassaged RIT4385, were also detected in RIT4385-
infected Vero or MDCK cells, at similar levels to the unpassaged
virus, indicating that RIT4385 is a more stable virus mixture com-
pared to JL-CK.
anger sequencing of JL-CK plaques. Unpassaged virus and virus isolated from JL-CK
DCK cell lysates, 3 d.p.i. are compared in the middle section. Mutation frequencies
 the lower section.
550Q L557P N56T C244R P93S F295S E569K D311G
2 26.5 40.5 97.5 45.3 27.3 96.9 43.4
. 21.3c n.d. n.d. n.d. n.d. n.d. n.d.
4 38 96 38 4 96 38
0 9.7 42.2 95.6 39.9 11.0 95.8 35.1
. 30.8 n.d. n.d. n.d. n.d. n.d. n.d.
1 23.2 31.7 89.5 31.0 26.3 89.7 29.5
. 33.1 n.d. n.d. n.d. n.d. n.d. n.d.
6 1.2 25.7 99.9 27.2 1.2 99.9 26.0
4 n.d. 5.1 100 5.8 n.d. 100 5.5
 n.d. 3.0 100 3.8 0.3 99.9 3.5
ial, c Mutation in non-coding region, * data for Vero and MDCK lysates are the mean
ys post infection.
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Fig. 3. (A) Progeny virus titration on Vero cells after a 7 day timecourse assay on
Vero cells. Viruses were inoculated at a MOI  0.0001. Progeny viruses were titrated
in  triplicate and plotted as pfu/ml of cell lysate. (B) Measurement of plaque size of
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RL-CK, RIT4385 and JL-CK variants using ImageJ. The “Parent” panel is the isolated
arent-like variant which has the identical sequence to RIT4385. The data plotted is
he number of plaques with corresponding plaque size, measured in ImageJ units.
.5. In vitro growth of JL-CK variants
To compare the growth of the individual variants with JL-
K and RIT4385, we propagated each virus in Vero cells over 7
ays. Fig. 3A shows JL-CK5 grew slowest, reaching maximum titre
1.46 × 106 pfu/ml) at 5 d.p.i, whilst JL-CK1 produced the highest
irus titre (1.35 × 107 pfu/ml), in the shortest time (3 d.p.i.). All vari-
nts and the JL-CK vaccine produced higher titres of virus than
IT4385. We  titrated the JL-CK variants to identify if the smallerne 33 (2015) 4586–4593
plaque phenotype could be attributed to one particular mutation.
Plaque analysis depicted in Fig. 3B showed that JL-CK3, JL-CK4 and
JL-CK5 all displayed the smaller plaque phenotype, suggesting that
Ter550Q, which is common to all of these variants, may  play a role
in this phenotype.
3.6. Neurovirulence potential of JL-CK and variants
The neonatal rat model has been proposed for neurovirulence
safety testing of MuV  [29,33]. The neurovirulence potential of JL-
CK, RIT4385 and Mu90 was compared. Fig. 4 shows the results from
individual rat brains. On average, JL-CK has higher neurovirulence
potential than RIT4385 (p = 0.0035), but when compared to Mu90,
a neurovirulent MuV  [29], the hydrocephalus observed in JL-CK
was signiﬁcantly less (p < 0.001). We  observed variation between
individual animals.
Fig. 5 shows the neurovirulence potential of the isolated JL-
CK variants, conﬁrming the difference observed between JL-CK
and RIT4385 shown in Fig. 4, albeit slightly less in this instance
(p = 0.0478). JL-CK1 and JL-CK5 produced increased ventricle sizes
compared to RIT4385 (*p  = 0.0406 and **p = 0.0100 respectively),
suggesting they may  have increased neurovirulence potential.
As expected, the parent-like virus behaved like RIT4385, as did
JL-CK3 (p = 0.1055) and JL-CK4 (p = 0.162). JL-CK2 showed signiﬁ-
cantly lower neurovirulence potential compared to both RIT4385
(p = 0.0181) and JL-CK (p = 0.0032).
3.7. Variant population dynamics after in vivo passage
Given the mixed population present in JL-CK and the difference
in the neurovirulence scores of each variant it was of interest to
examine variation of the virus subpopulations after growth in rat
brains. Deep sequencing was performed on three brains 4 d.p.i. with
JL-CK virus, Table 1, lower section. Compared with the inoculate
(JL-CK) or the plaque data, the frequency of most of the mutations
decreased. The frequencies of G/Ant92, C244R and E569K mutations,
present in all JL-CK variants, remained mostly unchanged. How-
ever, K36R in the nucleoprotein was signiﬁcantly more prominent
after growth of the virus in vivo with a 9.6-fold increase, sug-
gesting that JL-CK1 predominantly grew in the rat brain. JL-CK4
was present but at lower frequency than in Vero cells (∼3.5-fold
decrease). The results obtained from each animal were largely con-
sistent, although the difference was  less prominent in one animal
(RNV1). Growth of JL-CK vaccine in vivo preferentially selected JL-
CK1. The JL-CK5 variant did not appear to grow effectively despite
being one of the most virulent variants when tested individually
(Fig. 5).
4. Discussion
JL-CK and RIT4385 are two related mumps  vaccine viruses that
provide different levels of protection against MuV. The JL-CK vac-
cine was thought to be equivalent to RIT4385 and has been used
in some countries [26,34]. However, little is known about the
passage history of JL-CK and its production on primary canine
kidney cells raised additional concerns. When reports emerged
about a potential failure of the vaccine to protect against mumps
[24,26], we hypothesised that it differs from the RIT4385 strain.
MuV  is known to adapt to many cell lines and different growth
conditions can alter the ratio of Jeryl Lynn MuV  subpopulations
[19,20,35]. Unpublished data from our lab and others [27,36] sug-
gested that Vero cells may  alter MuVs. The objective of this study
was to identify the differences and to compare the two vaccines
at the genomic level and in in vitro and in vivo biological assays.
Our data show that both vaccines derive from the same Jeryl
Lynn-5 strain, but plaques formed by JL-CK were small compared
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Fig. 4. Neurovirulence scoring from neonatal rat brains 25 days after inoculation with JL-CK, RIT4385 or Mu90. Neurovirulence calculated by measuring the cross-sectional
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inetics, the yield from JL-CK was far higher. Deep sequencing
uggested not all variants in the JL-CK vaccine produced plaques
qually well in Vero cells. We  identiﬁed selection of a subpo-
ulation within JL-CK (JL-CK1), conﬁrmed by plaque sequencing,
hich also grew faster in Vero cells compared to the other
ariants.
Sequencing of JL-CK revealed 14 polymorphisms throughout the
enome which have not been reported before. One is in the non-
oding leader (G/Ant92), a second is silent (L542L), all others result
n changes to the predicted amino acid sequence, mostly in the
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dentical to RIT4385. Three of the mutations (V529A, L542L and
557P) were also found in RIT4385 at a lower level, although L557P
as in a non-coding region.
JL-CK contains a more mixed population than RIT4385, con-
rmed by plaque isolation, with mutation frequencies consistent
ith sequence heterogeneity and deep sequencing results. Muta-
ion K36R was  identiﬁed at low frequency by deep sequencing
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ig. 5. Neurovirulence scoring from neonatal rat brains 25 days after inoculation
ith JL-CK, RIT4385 or JL-CK variants. The data shown is from six brains from each
roup, with measurements taken from four sections of each brain. An increase in
eurovirulence compared to RIT4385 was observed for JL-CK1 (*p = 0.0406) and
L-CK5 (**p = 0.0100). JL-CK displayed an increase in neurovirulence potential com-
ared to the parent-like variant isolated from JL-CK (***p = 0.0440).le brain. The data shown is from nine brains from each group (except Mu90, n = 3),
ease in neurovirulence score compared to RIT4385 (*p = 0.0035 unpaired two-tailed
L-CK, RIT4385 or uninfected control (**p < 0.0001 unpaired two-tailed t-test for all).
of unpassaged JL-CK vaccine, but accumulated during passage in
Vero cells, in two independent assays after 3 or 10 days incuba-
tion, conﬁrming previous ﬁndings of selective pressure from Vero
cells [27,36]. Variant populations were less affected by passage on
MDCK cells, suggesting a key effect from the species of cell used.
RIT4385 was  more genetically stable on both Vero and MDCK cell
lines. We  did not assess virus growth or population dynamic within
other cell lines, and it is possible that additional phenotypes may
be observed.
The nucleoprotein contains between one (JL-CK1) and ﬁve (JL-
CK5) mutations. Ter550Q occurs in JL-CK3, JL-CK4 and JL-CK5,
extending the nucleoprotein by 21 amino acids, conﬁrmed by
mass spectrometry. Plaque isolates containing Ter550Q correlated
with a small plaque phenotype, although a deﬁnitive link would
require further studies using recombinant MuVs. The nucleopro-
tein is required for transcription, replication and virus assembly,
and antigenic sites have been found in its C-terminus [37,38]. It
is possible that elongation of the nucleoprotein may  affect these
functions.
JL-CK was more virulent than RIT4385 in the neonatal rat model
causing a higher degree of hydrocephalus, albeit not as virulent
as the wild-type Mu90. We  observed variation between animals,
which has been described for this model before [39]. Group sizes
were kept low in order to minimise animal usage. The differences
we observed between RIT4385 and Mu90 have been previously
reported [29]. However, in previous studies, differences between
closely related strains had been hard to detect, including the Jeryl
Lynn vaccine (containing JL-5 and JL-2) which was indistinguish-
able from RIT4385 [29].
Changes in viral genetic heterogeneity may impact on MuV
neurovirulence [40]. Interestingly, compared to JL-CK, the two vari-
ants which caused similar levels of hydrocephalus were JL-CK1
containing the fewest mutations and JL-CK5 containing the most,
suggesting the requirement of a combination of mutations for a
neurovirulence phenotype. Studies using recombinant MuVs have
shown that combinations of genes can alter neurovirulence in
neonatal rats [41].
JL-CK1 contains G/Ant92, C244R, E569K and K36R, which
increased 9.6-fold during in vivo growth in rat brains, suggest-
ing a role for these mutations in the neurovirulence phenotype
observed. The majority of the other mutations reduced in frequency
indicating a change in the virus subpopulation in vivo. The results
for the neurovirulence studies and deep sequencing of the rat
brains provide conﬂicting data, with previous studies suggesting a
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orrelation [41], although other biological factors may  play a role.
L-CK5 produces a high neurovirulence score but deep sequencing
uggests this virus does not replicate as effectively as the other
ariants in vivo. These ﬁndings are the subject of further study.
e found variation between animals infected with the same virus,
ith variant frequencies showing the same trend between animals
ut to varying degrees. In particular, the Ter550Q mutation (com-
on  to JL-CK3, 4 and 5) decreased in frequency compared to JL-CK
74.2%), in each animal the frequency was substantially different,
NV1 26.6%, RNV2 18.4% and RNV3 3.1%. This may  imply prefer-
ntial replication of JL-CK4 over JL-CK3 and JL-CK5 within the rat
rain and may  explain the variation seen within groups of animals
n the neurovirulence study.
Passage of MuV  through cell lines is the basis for attenuation.
he genetic differences between JL-CK and RIT4385 are presum-
bly a reﬂection of the different passage history of these viruses.
he high heterogeneity of JL-CK was unexpected. Our ﬁndings show
hat passaging JL-CK in vitro or in vivo affects the phenotype of the
iruses, with preferential selection of some virus populations over
thers, within a short time. The selection effects of the human host
n the virus are unknown and only few studies have investigated
hat happens to mumps  vaccine viruses after immunisation. For
xample, we have previously reported genomic variations in clin-
cal MuV  isolates following vaccination with the L-Zagreb vaccine
11].
This study conﬁrms the genetic instability of MuV  and adds to
he current evidence concerning the unstable nature of the MuV
enome. It also emphasises the importance of choosing suitable
ell substrates for mumps  vaccine manufacture. Genetic drift dur-
ng virus propagation has the potential to alter vaccine efﬁcacy or
afety. Deep sequencing may  be a useful tool to assess the genetic
eterogeneity between different batches, and variant frequency
ay  be a useful indicator of manufacturing consistency. However,
urther interpretation of the results is hampered by the fact that the
mpact of variations on vaccinated populations is not yet under-
tood. Our study brings to the forefront the fact that still very little
s known about MuV  pathogenesis and that the development of an
ffective animal model still proves to be elusive.
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